论文部分内容阅读
背景:目前国际上较为公认的CD34+细胞测定方法是ISHAGE单平台法及改进的双平台法,但因其成本昂贵,不太适合国内推广。目的:探索一种对动员外周血中CD34+细胞动态的简便有效的测定方法,以期在白血病等血液病的治疗上达到最佳移植效果。设计:非随机对照实验。地点和对象:动员外周血样本取自上海市长海医院34例异体或自体干细胞移植供体的病例。干预:由于CD34+细胞含量极少,其位置很容易受到B细胞和单核细胞的非特异结合的干扰。采用小鼠源性抗体直接标记法,会有效地减少这种干扰,增加检测的敏感度和特异性。主要观察指标:观察CD34+细胞在CD45/SSC窗口中的分布特征。结果:利用本方法可有效地测定CD34+细胞的相对含量为0.05%～0.1%,并且在药物动员后的第5,6天,多数患者外周血中CD34+细胞数量达到峰值,某些患者甚至超过1%。结论:本方法可对动员外周血中微量的CD34+细胞进行有效的动态监测,在临床上为适时采集干细胞并进行造血干细胞移植提供了重要的参考依据。
BACKGROUND: Currently, the internationally accepted method for determining CD34 + cells is the ISHAGE single-platform method and the improved dual-platform method. However, due to its high cost, it is not suitable for domestic promotion. Objective: To explore a simple and effective method for mobilizing the CD34 + cells in peripheral blood to achieve the best transplantation effect in the treatment of hematological diseases such as leukemia. Design: Non-randomized controlled experiment. Location and Subjects: Mobilized peripheral blood samples were obtained from 34 cases of allogeneic or autologous stem cell donor donors in Shanghai Changhai Hospital. Intervention: Due to the minimal amount of CD34 + cells, its location is susceptible to interference by non-specific binding of B cells and monocytes. Using mouse-derived antibody direct labeling method will effectively reduce this interference and increase the sensitivity and specificity of detection. MAIN OUTCOME MEASURES: The distribution of CD34 + cells in the CD45 / SSC window was observed. Results: The relative content of CD34 + cells was 0.05% ~ 0.1%. The number of CD34 + cells in the peripheral blood of most patients peaked on the 5th and 5th day after drug mobilization. In some patients, the number of CD34 + cells even exceeded 1 %. Conclusion: This method can effectively mobilize trace amount of CD34 + cells in peripheral blood and provide an important reference for collecting stem cells in time and performing hematopoietic stem cell transplantation in clinic.